Pharma's Patent Cliff: $200B in Annual Revenue at Risk by 2030

Between 2025 and 2030, drugs generating over $200 billion in annual revenue will lose patent protection, triggering a scramble among global pharmaceutical giants to plug the gaps. Companies are racing to acquire or develop new assets, with oncology drugs, obesity treatments, RNA therapies and gene therapies drawing the most attention.